Clinical Programs
Accelerating Cancer Immunotherapy Through Global Clinical Trials
The Cancer Research Institute’s (CRI) Clinical Accelerator and global immunotherapy trials network unites academia and industry to fast-track cancer immunotherapy from the lab to the clinic. Our clinical programs support patient access to groundbreaking treatments through collaborative, multi-center trials designed to test the most promising immunotherapies across a wide range of cancers.
CRI’s clinical programs are designed to:
- Test next-generation immunotherapies in multi-center clinical trials
- Expand patient access to innovative, science-backed cancer treatments
- Improve outcomes through collaborative, data-driven research
Discover how CRI’s immunotherapy clinical programs are shaping the future of cancer care.
Clinic and Laboratory Integration Program (CLIP)
Translating of basic laboratory discoveries into novel therapies
LOI Deadline
December 1
Total Funding
$300,000
Clinical Innovator
Support for innovative immunotherapy clinical trials
Protocol Concept Deadline
December 1
Total Funding
$1M
Technology Impact Award
Addressing the gap between technology development and clinical application of cancer immunotherapies
LOI Deadline
November 15
Total Funding
$300,000
CRI Awards & Honors
Each year, CRI bestows its highest scientific honors – The William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, and the Frederick W. Alt Award for New Discoveries in Immunology – upon leading scientists whose research has made a significant impact on the fields of immunology and cancer immunotherapy.
CRI Funded Scientists
These current and future scientific leaders in immunology and tumor immunology, from top academic research institutions, are advancing fundamental and applied discoveries that impact cancer research. From bench to bedside, CRI is ushering in the next generation of cancer immunotherapy innovations.